background
bacteria
virus
equal
associ
risk
acut
episod
asthmalik
symptom
young
children
suggest
antibiot
potenti
treatment
episod
aim
assess
eff
ect
azithromycin
durat
respiratori
episod
young
children
recurr
asthmalik
symptom
hypothesis
reduc
durat
symptomat
period
method
randomis
doubleblind
placebocontrol
trial
recruit
children
age
year
diagnos
recurr
asthmalik
symptom
copenhagen
prospect
studi
asthma
childhood
cohort
birth
cohort
consist
gener
danish
popul
zealand
includ
copenhagen
exclus
criteria
macrolid
allergi
heart
liver
neurolog
kidney
diseas
treatment
one
clinic
sign
pneumonia
respiratori
frequenc
breath
per
min
fever
creactiv
protein
concentr
nmoll
mgl
episod
asthmalik
symptom
last
least
day
randomli
alloc
cours
azithromycin
oral
solut
mgkg
per
day
placebo
thorough
examin
studi
physician
copenhagen
prospect
studi
asthma
research
unit
episod
randomli
alloc
independ
previou
treatment
computergener
list
random
number
block
ten
gener
pharmaci
glostrup
investig
children
mask
youngest
child
turn
year
age
throughout
data
valid
analysi
phase
primari
outcom
durat
respiratori
episod
treatment
verifi
ed
prospect
daili
diari
analys
poisson
regress
analys
per
protocol
exclud
without
primari
outcom
measur
receiv
treatment
trial
regist
clinicaltrialsgov
number
find
nov
jan
randomli
alloc
asthmalik
episod
children
azithromycin
placebo
mean
durat
episod
treatment
day
children
receiv
azithromycin
compar
day
children
receiv
placebo
azithromycin
caus
signifi
cant
shorten
episod
ci
p
eff
ect
size
increas
earli
initi
treatment
show
reduct
episod
durat
treatment
initi
day
episod
compar
initi
day
p
note
diff
erenc
clinic
advers
event
azithromycin
episod
includ
fi
nal
analysi
placebo
group
investig
bacteri
resist
pattern
treatment
interpret
azithromycin
reduc
durat
episod
asthmalik
symptom
young
children
suggest
drug
could
role
acut
manag
exacerb
research
need
disentangl
infl
ammatori
versu
antimicrobi
aspect
relat
childhood
asthma
often
preced
recurr
episod
troublesom
lung
symptom
relat
airway
infect
fi
rst
year
life
treatment
episod
repres
major
unmet
clinic
need
common
caus
admiss
hospit
young
children
reason
stress
anxieti
famili
caus
major
draw
healthcar
resourc
discov
birth
cohort
copenhagen
prospect
studi
asthma
childhood
copsac
previou
birth
cohort
children
born
mother
asthma
airway
bacteria
haemophilu
infl
uenza
streptococcu
pneumonia
moraxella
catarrhali
respiratori
virus
least
one
picornaviru
respiratori
syncyti
viru
coronaviru
parainfl
uenzaviru
infl
uenza
viru
human
metapneumoviru
adenoviru
bocaviru
equal
close
associ
episod
asthmalik
symptom
fi
rst
year
life
bacteria
virus
occur
togeth
case
challeng
previou
hypothesi
episod
asthmalik
symptom
age
group
larg
viral
induc
fi
nding
suggest
bacteria
might
play
equal
part
pathogenesi
episod
treatment
antibiot
might
amelior
symptom
present
guidelin
recommend
antibiot
treatment
earli
asthmalik
episod
yet
wide
use
randomis
control
trial
rct
azithromycin
treatment
episod
troublesom
lung
symptom
young
children
follow
prospect
new
unselect
copenhagen
prospect
studi
asthma
childhood
copsac
birth
cohort
randomis
doubleblind
placebocontrol
trial
recruit
children
copsac
cohort
singlecentr
populationbas
birth
cohort
children
recruit
gener
danish
popul
zealand
includ
copenhagen
week
age
follow
prospect
copenhagen
prospect
studi
asthma
childhood
copsac
research
unit
copenhagen
naestv
denmark
deep
clinic
phenotyp
children
age
year
diagnos
recurr
asthmalik
symptom
troublesom
lung
symptom
defi
ned
procedur
section
elig
time
episod
troublesom
lung
symptom
last
least
day
exclus
criteria
macrolid
allergi
heart
liver
neurolog
kidney
diseas
treatment
one
clinic
sign
pneumonia
respiratori
frequenc
breath
per
min
higher
fever
higher
creactiv
protein
crp
concentr
nmoll
mgl
higher
mother
copsac
cohort
also
particip
medic
trial
pregnant
may
receiv
dietari
supplement
infl
uenza
vaccin
addit
detail
baselin
characterist
cohort
outlin
copsac
cohort
design
report
trial
approv
ethic
committe
copenhagen
danish
data
protect
agenc
danish
health
medicin
author
parent
children
gave
written
oral
inform
consent
enrol
particip
complet
biobank
publicli
avail
danish
nation
biobank
entir
copsac
dataset
includ
rctspecifi
c
data
current
transfer
publicli
avail
databas
danish
data
archiv
episod
troublesom
lung
symptom
occur
age
year
maximum
seven
treatment
per
child
randomis
individu
either
azithromycin
placebo
treatment
randomli
alloc
pharmaci
glostrup
copenhagen
denmark
computergener
list
random
number
block
ten
copi
randomis
code
kept
seal
envelop
research
site
pharmaci
investig
particip
famili
mask
treatment
assign
youngest
child
turn
year
age
throughout
data
valid
analysi
phase
assess
primari
outcom
mask
subanalys
evid
studi
find
public
copenhagen
prospect
studi
asthma
childhood
show
bacteria
virus
equal
associ
risk
acut
episod
asthmalik
symptom
young
children
suggest
antibiot
azithromycin
could
help
manag
episod
search
pubm
oct
languag
limit
variou
combin
search
term
rct
childhood
asthma
wheez
antibiot
identifi
ed
previou
randomis
control
trial
treatment
antibiot
asthma
wheezi
exacerb
focus
mainli
childhood
asthma
search
led
us
new
articl
also
identifi
ed
relev
old
public
background
materi
investig
two
randomis
trial
conclud
benefi
cial
eff
ect
treatment
acut
exacerb
led
present
guidelin
recommend
antibiot
treatment
episod
acut
asthmalik
symptom
studi
knowledg
fi
rst
randomis
control
trial
azithromycin
treatment
acut
episod
asthmalik
symptom
children
age
year
histori
recurr
episod
fi
nding
show
clinic
signifi
cant
shorten
symptom
durat
intervent
present
guidelin
recommend
antibiot
treatment
episod
asthmalik
symptom
young
children
yet
antibiot
remain
among
commonli
prescrib
drug
episod
fi
nding
suggest
azithromycin
might
benefi
cial
medic
assess
acut
asthmalik
episod
young
children
known
histori
symptom
without
clinic
sign
pneumonia
eff
ect
azithromycin
compar
narrowspectrum
antibiot
whether
longterm
eff
ect
associ
recurr
use
azithromycin
need
investig
troublesom
lung
symptom
consist
cough
wheez
dyspnoea
sever
aff
ect
wellb
child
monitor
use
daili
diari
card
fi
lled
parent
birth
defi
ned
episod
least
consecut
day
troublesom
lung
symptom
point
request
parent
brought
child
copsac
research
unit
acut
visit
use
composit
score
troublesom
lung
symptom
describ
asthmalik
symptom
children
score
previous
valid
use
clinic
observ
cohort
studi
young
children
randomis
control
trial
acut
visit
diari
card
review
famili
train
copsac
paediatrician
valid
symptom
defi
nition
sever
addit
research
paediatrician
thorough
physic
examin
consist
assess
fever
tachypnoea
chest
recess
wheez
lung
heart
auscult
examin
skin
ear
nose
throat
furthermor
measur
crp
concentr
detect
limit
nmoll
mgl
peripher
blood
quickread
instrument
orion
diagnostica
espoo
finland
collect
hypopharyng
aspir
use
soft
suction
cathet
pass
nose
hypopharynx
previous
describ
cultur
sampl
isol
airway
bacteri
pathogen
h
infl
uenza
pneumonia
catarrhali
obtain
nasopharyng
aspir
viral
identifi
cation
pcr
viral
airway
pathogen
analys
rhinovirus
respiratori
syncyti
viru
rsv
enterovirus
treat
episod
troublesom
lung
symptom
agonist
salbutamol
airomir
teva
kongen
lyngbi
denmark
inhal
pressuris
meter
dose
inhal
deliv
via
spacer
aerochamb
trudel
medic
intern
london
canada
need
ad
mg
montelukast
even
week
children
previous
benefi
ted
treatment
ad
prednisolon
mgkg
per
day
day
sever
episod
discret
attend
paediatrician
copsac
research
unit
recurr
troublesom
lung
symptom
diagnos
child
daili
diari
record
fi
episod
troublesom
lung
symptom
within
month
week
continu
symptom
sever
acut
episod
need
oral
prednisolon
hospit
admiss
diagnosi
algorithm
previous
valid
atrisk
copsac
birth
cohort
diagnosi
recurr
troublesom
lung
symptom
gave
children
cours
fl
uticason
flixotid
glaxosmithklin
uk
inhal
pressuris
meter
dose
inhal
deliv
via
spacer
twice
daili
second
relaps
troublesom
lung
symptom
occur
cessat
inhal
corticosteroid
initi
cours
inhal
corticosteroid
children
diagnos
recurr
troublesom
lung
symptom
particip
trial
prescrib
azithromycin
placebo
copsac
research
unit
subsequ
acut
episod
troublesom
lung
symptom
occur
diagnosi
gave
azithromycin
oral
solut
mgkg
per
day
close
bottl
teva
consecut
day
match
placebo
similar
look
tast
pharmaci
glostrup
primari
outcom
diaryverifi
ed
durat
episod
troublesom
lung
symptom
initi
treatment
secondari
outcom
time
treatment
next
episod
troublesom
lung
symptom
number
episod
turn
sever
exacerb
need
oral
steroid
admiss
hospit
durat
agonist
use
treatment
seriou
advers
event
advers
event
gastrointestin
symptom
infect
document
daili
diari
card
hospit
record
base
power
calcul
durat
episod
troublesom
lung
symptom
age
year
children
previou
copsac
cohort
independ
episod
need
detect
diff
erenc
day
durat
episod
power
p
valu
sd
durat
episod
day
analys
durat
episod
troublesom
lung
symptom
agonist
use
treatment
poisson
regress
log
link
type
regress
ideal
model
count
captur
skew
varianc
heterogen
provid
easytointerpret
quantifi
cation
eff
ect
rel
chang
mean
count
model
includ
fi
xed
eff
ect
categor
variabl
episod
number
eff
ect
treatment
includ
random
eff
ect
child
account
heterogen
children
analys
factor
potenti
modifi
treatment
eff
ect
robust
poisson
regress
account
withinchild
correl
obtain
infer
mean
generalis
estim
equat
procedur
work
independ
assumpt
analys
gap
time
episod
cox
regress
includ
frailti
share
gap
time
within
child
account
betweenchild
heterogen
includ
fi
xed
eff
ect
treatment
preced
episod
model
stratifi
ed
baselin
hazard
episod
number
obtain
estim
maximum
likelihood
estim
wald
ci
p
valu
cutoff
analys
use
r
version
addon
packag
primari
analys
per
protocol
exclud
without
primari
outcom
measur
receiv
treatment
safeti
analys
includ
without
primari
outcom
measur
receiv
studi
treatment
trial
monitor
good
clinic
practic
unit
copenhagen
univers
hospit
copenhagen
denmark
trial
regist
clinicaltrialsgov
number
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
js
cbp
hb
access
raw
data
correspond
author
full
access
data
studi
fi
nal
respons
decis
submit
public
children
enrol
main
cohort
diagnos
recurr
troublesom
lung
symptom
fi
rst
year
life
nov
jan
randomli
alloc
episod
trial
treatment
azithromycin
placebo
fi
gure
children
analys
exclud
ten
episod
analysi
fi
group
nine
miss
diari
inform
azithromycin
four
placebo
fi
one
azithromycin
group
treatment
never
given
child
mean
age
randomis
year
sd
mean
number
randomis
child
treatment
sd
episod
analys
azithromycintr
episod
placebotr
episod
child
receiv
concurr
treatment
inhal
corticosteroid
episod
child
receiv
concurr
treatment
montelukast
azithromycintr
episod
placebotr
episod
treatment
compli
episod
one
azithromycin
treatment
never
given
three
treatment
discontinu
initi
one
azithromycin
group
two
placebo
group
children
complet
clinic
followup
inclus
studi
age
year
baselin
characterist
diff
er
signifi
cantli
particip
trial
children
diagnos
recurr
troublesom
lung
symptom
copsac
cohort
particip
tabl
mean
total
durat
respiratori
episod
day
episod
durat
randomis
unrel
sex
mother
smoke
statu
allerg
sensitis
inhal
food
allergen
month
month
atop
dermat
genet
risk
variant
appendix
figur
show
proport
symptomat
children
daybyday
day
treatment
show
shorten
symptomat
period
treatment
azithromycin
averag
number
symptom
day
azithromycin
treatment
day
versu
day
placebo
correspond
calcul
reduct
episod
length
ci
p
within
child
due
azithromycin
treatment
tabl
restrict
analysi
fi
rst
randomis
treatment
child
substanti
signifi
cant
reduct
symptom
durat
p
treatment
azithromycin
correspond
mean
durat
day
azithromycin
versu
day
placebo
eff
ect
azithromycin
increas
durat
symptom
treatment
shorter
show
reduct
episod
durat
treatment
initi
day
episod
compar
initi
day
p
figur
show
reduct
episod
durat
azithromycin
treatment
function
episod
durat
treatment
less
median
valu
day
note
diff
erenti
eff
ect
episod
present
fever
increas
crp
concentr
nmoll
mgl
treatment
equal
eff
ectiv
episod
without
object
wheez
examin
research
clinic
tabl
presenc
pathogen
bacteria
signifi
cantli
modifi
treatment
eff
ect
compar
episod
without
detect
bacteria
azithromycin
eff
ectiv
episod
posit
h
infl
uenza
tabl
presenc
viru
modifi
treatment
eff
ect
azithromycin
none
detect
virus
signifi
cantli
modifi
ed
treatment
eff
ect
tabl
concurr
treatment
inhal
steroid
p
valu
montelukast
p
valu
signifi
cantli
modifi
treatment
eff
ect
respons
equal
appendix
note
diff
erenc
treatment
group
day
treatment
respect
seriou
advers
event
gastrointestin
symptom
infect
document
daili
diari
card
hospit
record
appendix
azithromycin
signifi
cantli
reduc
durat
physicianverifi
ed
episod
asthmalik
symptom
children
age
year
histori
recurr
asthmalik
symptom
durat
decreas
azithromycin
treatment
improv
treatment
start
earli
episod
azithromycin
longterm
eff
ect
risk
subsequ
episod
studi
substanti
strengthen
prospect
longitudin
daili
diari
record
lung
symptom
develop
attack
valid
studi
paediatrician
acut
visit
copsac
serv
primari
healthcar
centr
birth
cohort
ensur
standardis
approach
diagnosi
treatment
improv
reliabl
diagnos
compar
report
commun
doctor
retrospect
inform
parent
diagnosi
base
algorithm
symptom
quantiti
analys
valid
detail
appli
previou
rct
inhal
corticosteroid
young
children
atrisk
copsac
birth
cohort
strict
diagnost
procedur
paramount
clinic
assess
diagnos
treatment
otherwis
poorli
standardis
commun
diffi
cult
young
children
later
life
indepth
clinic
assess
respiratori
episod
studi
paediatrician
randomis
includ
thorough
object
examin
crp
concentr
measur
research
clinic
ensur
valid
homogen
primari
outcom
exclus
children
clinic
sign
pneumonia
assess
minimis
possibl
azithromycin
eff
ect
driven
treatment
bacteri
pneumonia
misclassifi
ed
episod
asthmalik
symptom
anoth
strength
centralis
longitudin
clinic
followup
cohort
research
team
well
establish
routin
clinic
cohort
studi
routin
ensur
high
followup
cohort
randomis
children
complet
full
followup
year
age
randomis
treatment
unavail
obtain
airway
sampl
treatment
episod
episod
miss
result
generalis
similar
group
children
known
histori
recurr
asthmalik
symptom
without
concomit
treatment
inhal
steroid
episod
durat
least
day
import
limit
data
pertain
children
episod
durat
treatment
detail
clinic
histori
acut
worsen
judg
studi
clinician
generalis
liber
set
initi
home
parent
children
mild
diseas
studi
fi
rst
knowledg
investig
show
eff
ect
azithromycin
treatment
acut
respiratori
episod
young
children
histori
recurr
asthmalik
symptom
cohort
design
power
explor
eff
ect
third
children
experi
episod
asthmalik
symptom
relat
airway
infect
year
age
shorten
episod
therefor
clinic
signifi
cant
child
famili
healthcar
user
societi
note
azithromycin
mark
eff
ect
relat
given
type
episod
independ
trigger
clinic
present
symptom
durat
intervent
suggest
broad
applic
sensit
analysi
restrict
episod
fi
rst
randomis
valid
primari
fi
nding
asthmalik
episod
young
children
probabl
repres
heterogen
clinic
syndrom
importantli
exclud
typic
pneumonia
base
predefi
ned
clinic
criteria
furthermor
children
undetect
concentr
crp
fever
randomis
treatment
eff
ect
similar
children
strongli
suggest
eff
ect
azithromycin
due
misclassifi
cation
pneumonia
azithromycin
treatment
particularli
eff
ectiv
children
treat
shortli
symptom
debut
fi
nding
make
us
specul
azithromycin
mainli
act
acut
infl
ammatori
infecti
process
relat
exacerb
rather
persist
underli
infl
ammat
hypothesi
support
absenc
eff
ect
time
next
episod
altern
azithromycin
act
clear
bacteri
pathogen
indirectli
respons
respiratori
episod
subsequ
coinfect
viral
trigger
therefor
treatment
eff
ectiv
initi
earli
episod
initi
late
studi
base
previou
birth
cohort
studi
discov
pathogen
airway
bacteria
respiratori
virus
equal
close
associ
acut
episod
asthmalik
symptom
young
children
mostli
occur
togeth
fi
nding
studi
treatment
eff
ect
strong
even
episod
bacteri
pathogen
detect
suggest
eff
ect
azithromycin
antibacteri
macrolid
antibiot
activ
common
airway
pathogen
bacteria
atyp
bacteria
also
antiinfl
ammatori
activ
possibl
antivir
eff
ect
studi
macrolid
adult
sever
asthma
episod
ambigu
macrolid
reportedli
reduc
exacerb
adult
asthma
type
characteris
chronic
neutrophil
infl
ammat
inde
recurr
asthmalik
symptom
young
children
also
characteris
neutrophil
infl
ammat
particular
might
present
episod
trigger
h
infl
uenza
correspond
fi
nding
stronger
azithromycin
eff
ect
episod
trigger
h
infl
uenza
viral
infect
gener
predict
alter
eff
ect
azithromycin
treatment
low
number
viral
speci
group
limit
conclus
drawn
eff
ect
modifi
cation
specifi
c
virus
thu
antibacteri
antiinfl
ammatori
antivir
pathway
azithromycin
could
contribut
shorten
episod
length
observ
studi
rule
eff
ect
note
mainli
antiinfl
ammatori
episod
trigger
h
infl
uenza
induc
neutrophil
infl
ammat
azithromycin
also
reduc
episod
durat
children
without
evid
bacteri
infect
rct
treatment
azithromycin
rsvposit
children
show
reduct
neutrophil
marker
interleukin
day
azithromycin
treatment
fi
nding
could
point
toward
antiinfl
ammatori
eff
ect
primari
mediat
fi
nding
also
explain
fi
nding
previou
rct
fail
show
treatment
eff
ect
nonantiinfl
ammatori
antibiot
acut
exacerb
childhood
asthma
present
guidelin
recommend
antibiot
treatment
episod
asthmalik
symptom
young
children
yet
among
commonli
prescrib
drug
episod
usa
europ
data
suggest
eff
ect
azithromycin
acut
asthmalik
episod
therebi
identifi
potenti
futur
treatment
provid
suffi
cient
evid
recommend
treatment
clinic
practic
eff
ect
azithromycin
compar
narrowspectrum
antibiot
whether
longterm
eff
ect
associ
recurr
use
need
investig
keenli
awar
potenti
ecolog
issu
relat
use
antibiot
term
bacteri
ecolog
resist
macrolid
resist
organ
caus
respiratori
ill
children
alreadi
issu
futur
research
establish
choic
antimicrobi
treatment
criteria
treatment
take
societ
aspect
consider
identifi
strong
eff
ect
modifi
er
object
clinic
measur
concomit
treatment
microbiolog
profi
le
presenc
h
infl
uenza
data
suggest
eff
ect
increas
start
earli
episod
futur
studi
might
help
identifi
specifi
c
diseas
phenotyp
biomark
direct
treatment
specifi
c
group
young
children
result
studi
identifi
potenti
treatment
common
childhood
diseas
better
treatment
option
need
current
avail
better
treatment
might
help
allevi
substanti
diseas
burden
children
famili
societi
hb
conceiv
design
carri
studi
acquir
analys
interpret
data
wrote
report
js
blc
kb
contribut
design
studi
js
acquir
analys
interpret
data
draft
report
cbp
statist
analys
ss
kak
cultur
identifi
ed
bacteria
tkf
identifi
ed
virus
blc
nhv
eb
tmp
rkv
amm
hmw
st
hwh
la
kb
collect
interpret
data
wrote
report
coauthor
contribut
substanti
analys
interpret
data
provid
import
intellectu
input
approv
fi
nal
version
manuscript
hb
receiv
fund
research
member
research
staff
paid
consult
chiesi
author
declar
compet
interest
